Both of these biomarkers are included in the company’s commercially available Precivity™ blood tests, which help healthcare providers determine...
“The first patient dosed with an AdvanCell therapeutic candidate represents a major milestone for the Company, our scientists, clinical trial sites, ...
-Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, an...
1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia. Top-line results for on-going, 52-week...
Fragile X and Autism collectively impact over seven million individuals in the United States and Europe. Despite this staggering number, there are currentl...
Phase II results demonstrated significant albuminuria reductions by up to 39.5% vs. placebo when BI 690517, a novel selective aldosterone synthase inhibi...
Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a new generation of its distributed liquid bi...
Under the terms of the option agreement, AbbVie has the option to acquire a co-exclusive license to develop, manufacture, and commercialize reproxalap in t...
Initial EVX-01 Phase 2 data confirms the strong Phase 1 results After undergoing EVX-01 treatment, a significant and continuous tumor reduction was ...
Renaissance BioScience Corp., a leader in bioengineering for the global agriculture, animal health, human medicine, and food industries, is pleased to anno...
LumaCyte, a leading innovator in advanced single cell analysis technology and instrumentation, is proud to announce the launch of their newly redesigned fl...
American College of Gastroenterology (ACG) gives BLUE-C study late breaker status at 2023 annual meeting with presentation of the only head-to-head study r...
“Traditionally, clients looking to purchase research models would review a static digital catalog, and follow-up with a phone call or email to our or...
To support emerging precision therapies and improve patient outcomes by increasing access to reliable genomic testing needed to match patients with targete...
© 2025 Biopharma Boardroom. All Rights Reserved.
